Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

China has Entered the Era of Tumor Immunotherapy: Updates on the R&D Progress of Anti-PD-(L)1 Antibodies

PharmaSources/1℃March 06, 2019

Tag: antibodies , PD-1 , PD-L1 , Tumor Immunotherapy

PharmaSources Customer Service